Researchers from the University of Western Australia found that low doses of TNFα (tumor necrosis factor α) targeted to a pancreatic tumor enhanced the ability of immune cells (T cells) to get inside the tumor.
The Bacillus Calmette-Guérin vaccine works in superficial bladder cancer, treating early stage disease and cutting recurrences. Vitamin D is linked with boosting the immune system, so researchers are looking at mice with bladder cancer to see what happens when you combine the two.
Pancreatic cancer is hard to treat, but adding a cancer vaccine to standard chemotherapy could boost survival.
Galectin Therapeutics has started treating patients with advanced disease in a Phase I/II trial to see if combining its galectin inhibitor GM-CT-01 with a peptide-based cancer vaccine developed at the Ludwig institute improves the outcome of patients with advanced metastatic melanoma.
Biovest International's stock has risen by 15% on two pieces of news about its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, BiovaxID.
Cancer vaccines are becoming an increasingly attractive focus of study, but there are still perils and pitfalls along the way to success. Two recent studies have looked at ways to get around these, focusing on experimental cancer vaccines boosted by existing drugs.
Researchers at the Moffitt Cancer Center are developing "designer" lymph nodes that could be used to boost the effects of cancer vaccines.
Another site in the U.S. has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme.
Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.
Scancell, a U.K. spinout from the University of Nottingham, has completed recruitment for the Phase I trial of SCIB1, its therapeutic DNA vaccine for the treatment of melanoma.